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High activity of histone deacetylases (HDACs) causes epigenetic alterations associated with malignant cell behaviour. Consequently,
HDAC inhibitors have entered late-phase clinical trials as new antineoplastic drugs. However, little is known about expression and
function of specific HDAC isoforms in human tumours including prostate cancer. We investigated the expression of class I HDACs in
192 prostate carcinomas by immunohistochemistry and correlated our findings to clinicopathological parameters including follow-up
data. Class I HDAC isoforms were strongly expressed in the majority of the cases (HDAC1: 69.8%, HDAC2: 74%, HDAC3: 94.8%).
High rates of HDAC1 and HDAC2 expression were significantly associated with tumour dedifferentiation. Strong expression of all
HDACs was accompanied by enhanced tumour cell proliferation. In addition, HDAC2 was an independent prognostic marker in our
prostate cancer cohort. In conclusion, we showed that the known effects of HDACs on differentiation and proliferation of cancer
cells observed in vitro can also be confirmed in vivo. The class I HDAC isoforms 1, 2 and 3 are differentially expressed in prostate
cancer, which might be important for upcoming studies on HDAC inhibitors in this tumour entity. Also, the highly significant
prognostic value of HDAC2 clearly deserves further study.
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Prostate cancer is the most common malignant neoplasm in men
and ranks second only to lung cancer as a cause of tumour-related
death of males in the United States (Jemal et al, 2007). Although a
majority of patients have a relatively good prognosis after primary
treatment with prostatectomy or irradiation, this disease entity
also comprises a subgroup of highly aggressive neoplasms with a
dismal prognosis. So far, the estimation of the individual patient’s
prognosis is, despite considerable investigative efforts, unreliable,
which underscores the necessity of novel prognostic markers
(Andren et al, 2006). Organ-confined tumours might be treated
curatively with surgery, radiotherapy and hormonal ablation
alone; however, with the onset of metastases, the disease will
eventually take a lethal course (Carroll, 2005). Quite clearly, novel
treatment strategies complementing the therapeutic arsenal of
surgeons and oncologists in the fight against this neoplasm are
urgently needed.
Recently, an entirely new group of chemotherapeutics has
emerged, which target the enzyme family of histone deacetylases
(HDACs) and thus change the epigenetic configuration of tumour
cells (Li et al, 2005; Yoo and Jones, 2006). These substances, called
histone deacetylase inhibitors (HDIs), possess marked antineo-
plastic properties and have entered clinical trials for a broad
variety of malignant tumours including prostate cancer (Zhang
et al, 2006). To date, four HDAC classes comprising 18 isoenzymes
are known. Histone deacetylases are responsible for the deacetyla-
tion of histone tails, which leads to a tighter wrapping of the DNA
around the histone core and consequently alters gene transcription
(Minucci and Pelicci, 2006). Additionally, inhibition of deacetyla-
tion of a variety of proteins implicated in tumorigenesis by HDIs
might further contribute to the antitumour effects of these
substances (Mie Lee et al, 2003; Drummond et al, 2005; Floryk
and Huberman, 2005; Roy et al, 2005). Inhibition of class I and
class II members of this enzyme family by HDIs, such as valproic
acid (VPA) and suberoylanilide hydroxamic acid (SAHA), causes
growth arrest, differentiation and/or apoptosis of tumour cells
(Richon et al, 2001; Blaheta et al, 2005) and may dramatically
enhance radiation-induced apoptosis (Chinnaiyan et al, 2005).
Although some HDIs, including SAHA and VPA, are in late-phase
clinical trials, it is surprising to learn how little is known about the
contribution of specific HDAC isoforms to the tumorigenic
potential of HDACs.
In this study, we aimed to determine the expression patterns
of HDAC1, 2 and 3 in prostate cancer, using a large clinically
well-characterized patient cohort to clarify a diagnostic or
prognostic value of selected class I HDACs.
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Patient characteristics
One hundred and ninety-two patients (age: 46–73 years, median
62.5 years) who were diagnosed for prostate cancer at the Institute
of Pathology, Charite ´ – Universita ¨tsmedizin Berlin, after radical
prostatectomy, between 1991 and 2001, were included in this
study. The study has been approved by the Charite ´ University
Ethics Committee under the title ‘Retrospektive Untersuchung von
Gewebeproben mittels immunhistochemischer Fa ¨rbung und
molekularbiologischer Methoden’ (‘Retrospective analysis of tissue
samples by immunohistochemistry and molecular biological
techniques’) (EA1/06/2004) on 20 September 2004.
PSA levels were used as clinical surrogate markers for
preoperative tumour volume (preoperative PSA, data available
for 156 patients) and time to relapse (time course of postoperative
PSA, data available for 150 patients). For those patients for whom
all necessary data were available (n¼124), Kattan scores and
probability of 7-year disease-free survival (DFS) were calculated
using the respective postoperative nomogram for patients after
radical prostatectomy (Kattan et al, 1999).
None of the patients in our cohort received chemotherapy or
hormonal therapy before surgery. After prostatectomy, none of the
patients received adjuvant hormonal therapy; hormonal therapy
was usually initiated only when a relapse occurred. Patients with a
pT3 tumour and apical R1 situation received local postoperative
radiotherapy. Clinical follow-up data were available for 150
patients. A PSA recurrence, which was indicative of progression
of prostate cancer, was defined as a persistent increase of PSA from
the nadir value of p0.04ngml
 1. The median follow-up time of
patients still relapse-free at the end of analysis was 50 months
(mean: 61.9 months).
Tissue and clinicopathological data
All prostatectomy specimens were completely embedded and were
reviewed to establish stage and grade of the respective prostate
cancers. For the construction of our cohort, prostate tissue blocks
that contained large areas of prostate cancer and normal prostate
parenchyma were selected. Gleason sums were condensed into
a ‘low-grade’ (2–6), ‘intermediate-grade’ (7) and ‘high-grade’
(8–10) group for further analysis. The distribution of clinico-
pathological data in the study cohort is given in Table 1.
Immunohistochemistry
For immunohistochemical detection of HDAC isoforms on tissue
samples, prediluted (‘ready to use’) polyclonal rabbit IgG antibody
directed against HDAC1 (1:11; Abcam, Cambridge, UK), mono-
clonal mouse IgG antibody directed against HDAC2 (1:5000;
Abcam) and monoclonal mouse IgG antibody directed against
HDAC3 (1:500; Becton Dickinson, Franklin Lakes, NJ, USA) were
used on 3mm paraffin sections after a standard heat-induced
antigen retrieval as previously described (Noske et al, 2005).
Ki-67 (MIB-1) staining was performed with a Ventana
autostainer (Ventana, Tucson, AZ, USA) using a monoclonal
mouse IgG antibody (1:50; Dako, Glostrup, Denmark) under
standard conditions.
Evaluation of staining of tissue slides
Nuclear staining of HDAC isoforms was scored by applying a
semiquantitative immunoreactivity scoring (IRS) system that
incorporates the percentual area and the intensity of immuno-
reactivity, resulting in a score ranging from 0 to 12, as described
(Noske et al, 2005). Two clinical pathologists (WW and GK)
independently scored the cases. Carcinomas and prostatic
intraepithelial neoplasia (PIN), if present, were scored separately.
Differences in the evaluation were discussed at a multiheaded
microscope until consensus was reached. For statistical analysis,
cases exhibiting an IRS from 0 to 6 were lumped in an HDAC low
group, whereas cases with a higher IRS (7–12) were designated
HDAC high group.
The Ki-67 index was determined by counting Ki-67-positive
tumour cell nuclei per 100 tumour cells in a representative,
carefully selected tumour area. Mean proliferative activity of
Table 1 Overall expression of class I HDAC isoforms in prostate carcinoma as well as distribution of class I HDAC isoform expression in the study
population stratified for selected tumour parameters
Total HDAC1 low HDAC1 high P-value HDAC2 low HDAC2 high P-value HDAC3 low HDAC3 high P-value
All cases 192 (100%) 58 (30.2%) 134 (69.8%) 50 (26%) 142 (74%) 10 (5.2%) 182 (94.8%)
PSA p10ngml
 1 75 (48.1%) 23 (30.7%) 52 (69.3%) 0.610
+ 23 (30.7%) 52 (69.3%) 0.474
+ 4 (5.3%) 71 (94.7%) 1.000
+
PSA 410ngml
 1 81 (51.9%) 29 (35.8%) 52 (64.2%) 20 (24.7%) 61 (75.3%) 5 (6.2%) 76 (93.8%)
Age p65 134 (69.8%) 43 (32.1%) 91 (67.9%) 0.494
+ 29 (21.6%) 105 (78.4%) 0.048
+ 8 (6%) 126 (94%) 0.726
+
Age 465 58 (30.2%) 15 (25.9%) 43 (74.1%) 21 (36.2%) 37 (63.8%) 2 (3.4%) 56 (96.6%)
pT2 97 (50.5%) 32 (33%) 65 (67%) 0.580* 28 (28.9%) 69 (71.1%) 0.398* 5 (5.2%) 92 (94.8%) 0.925*
pT3 91 (47.4%) 24 (26.4%) 67 (73.6%) 21 (23.1%) 70 (76.9%) 5 (5.5%) 86 (94.5%)
pT4 4 (2.1%) 2 (50%) 2 (50%) 1 (25%) 3 (75%) 0 (0%) 4 (100%)
Gleason sum 2–6 70 (36.5%) 31 (44.3%) 39 (55.7%) 0.006* 24 (34.3%) 46 (65.7%) 0.047* 5 (7.1%) 65 (92.9%) 0.584*
Gleason sum 7 64 (33.3%) 14 (21.9%) 50 (78.1%) 15 (23.4%) 49 (76.6%) 2 (3.1%) 62 (96.9%)
Gleason sum 8–10 58 (30.2%) 13 (22.4%) 45 (77.6%) 11 (19%) 47 (81%) 3 (5.2%) 55 (94.8%)
R0 100 (52.1%) 29 (29%) 71 (71%) 0.754
+ 30 (30%) 70 (70%) 0.249
+ 5 (5%) 95 (95%) 1.000
+
R1 92 (47.9%) 29 (31.5%) 63 (68.5%) 20 (21.7%) 72 (78.3%) 5 (5.4%) 87 (94.6%)
HDAC1 low 58 (30.2%) — — — 23 (39.7%) 35 (60.3%) 0.007
+ 10 (17.2%) 48 (82.8%) o0.001
+
HDAC1 high 134 (69.8%) — — 27 (20.1%) 107 (79.9%) 0 (0%) 134 (100%)
HDAC2 low 50 (26%) 23 (46%) 27 (54%) 0.007
+ — — — 7 (14%) 43 (86%) 0.004
+
HDAC2 high 142 (74%) 35 (24.6%) 107 (75.4%) — — 3 (2.1%) 139 (97.9%)
HDAC3 low 10 (5.2%) 10 (100%) 0 (0%) o0.001
+ 7 (70%) 3 (30%) 0.004
+ —— —
HDAC3 high 182 (94.8%) 48 (26.4%) 134 (73.6%) 43 (23.6%) 139 (76.4%) — —
Ki-67 index mean 8.60 6.88 9.30 0.032
# 6.44 9.30 0.002
# 4.00 8.83 o0.001
#
Ki-67 index s.d. 6.62 0.82 0.63 0.61 0.64 0.63 0.53
DFS probability median 0.70 0.80 0.60 0.203
$ 0.83 0.60 0.036
$ 0.60 0.70 0.946
$
DFS probability quart. 0.3–0.9 0.30–0.91 0.30–0.86 0.40–0.93 0.30–0.85 0.20–0.90 0.30–0.90
DFS¼disease-free survival; HDAC¼histone deacetylase. In the first row overall distribution of the respective tumour parameters in the study population is listed.
+Fisher’s exact
test, *w
2-test for trends,
#unpaired t-test
$, Mann–Whitney U-test.
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sprostate carcinomas was 8.6% (s.d.: 6.62%) of tumour cells and
thus quite low in comparison to other solid human malignancies.
Statistical analysis
Statistical analyses were performed with SPSS 14.0 and GraphPad
Prism 4.0. Fisher’s exact and w
2-tests were applied to assess the
statistical significance of the associations between expression of
HDACs and clinicopathological parameters. Immunoreactivity
scores for HDAC expression in PIN and carcinomas were
correlated by Spearman’s rank order correlation. The Mann–
Whitney U-test was used to compare Kattan scores and
normogram probability of DFS in different HDAC expression
groups. Unpaired t-test was used to compare Ki-67 levels.
Univariate survival analysis was carried out according to
Kaplan–Meier, differences in survival curves were assessed with
the log-rank test. The Cox regression model was used for
multivariate survival analysis. P-values o0.05 were considered
significant.
RESULTS
Expression patterns of class I HDAC isoforms in prostate
tissue
Normal prostate tissue in the vicinity of prostate carcinomas was
evaluated for all 192 cases. HDAC staining of normal prostate
tissue showed a characteristic pattern with only minimal variation
between cases: nuclei of stromal cells of normal prostate
parenchyma displayed a discontinuous weak to moderate expres-
sion of HDAC1, HDAC2 and HDAC3. Luminal epithelial cells of
normal prostate glands showed a homogenous moderate positivity
for all three HDAC isoforms; basal cells were mostly negative
(Figure 1, Supplementary Figures S1–S3).
Strong nuclear HDAC1, HDAC2 and HDAC3 immunoreactivity
was seen in most adenocarcinomas (Figure 1, Supplementary
Figures S1–S3). However, staining intensity and the number of
cells stained varied depending on the HDAC isoform investigated.
Of 192 cases, 134 (69.8%) and 142 (74%) cases were scored high
for HDAC1 and HDAC2, respectively, whereas an even higher
50 m 50 m
50 m 50 m
50 m 50 m
AB
CD
EF
Figure 1 Class I HDAC expression in prostate tissue. (A) Moderate HDAC3 staining was evident in the nuclei of luminal epithelial cells (arrows) of
normal prostate glands, whereas the majority of basal epithelial cells revealed only weak HDAC positivity (arrowhead). Note occasional moderate HDAC3
expression in prostate stroma cells. Inset: autonomous neural plexus cells exhibiting strong HDAC3 nuclear staining. (B) High-grade PIN (arrows) with
strong nuclear positivity for HDAC2. (C) Microacinar prostate adenocarcinoma with only few tumour cell nuclei showing moderate expression of HDAC2.
This case was scored as HDAC2 low. (D) Prostate carcinoma with moderate nuclear expression of HDAC1 (arrows) in approximately 70% of tumour cells.
(E) Adenocarcinoma with homogenous strong nuclear expression of HDAC2 (arrows). Note adjacent normal prostate gland (arrowheads). (F) Perineural
microacinar neoplastic infiltrates exhibiting strong HDAC3 expression in approximately 70% of tumour cell nuclei.
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spercentage of cases (94.8%, 182 cases) showed a strong nuclear
positivity for HDAC3 (Table 1). In three cases, additional
cytoplasmic positivity, exclusively seen in HDAC2 immunostainings,
was observed in a minority of tumour cells (Supplementary Figure
S2). Completely negative cases (IRS 0) were not observed for
HDAC1, HDAC2 and HDAC3, indicating that a maintained
expression of these proteins is important for prostate cancer.
Expression of HDAC isoforms showed a high degree of
concordance (Po0.01, Table 1), suggesting a shared regulation.
Stromal cells of prostate cancers also displayed weak to moderate
nuclear positivity for all the three HDAC isoforms, which was
mostly due to positive staining in fibroblasts. If present, scattered
admixed inflammatory cells were positive, as well. Slight variations
in stromal HDAC expression between different carcinoma cases on
the one hand and carcinoma and normal parenchyma on the other
hand were noted but not scored.
Lesions of high-grade PIN in the vicinity of invasive carcinomas
were identified in 56 (HDAC1), 57 (HDAC2) and 67 (HDAC3)
cases, respectively (Figure 1, Supplementary Figures S1–S3). High
expression of HDACs was noted in 43 (76.8%), 36 (63.2%) and 66
(98.5%) cases for HDAC1, HDAC2 and HDAC3, respectively.
Expression of HDACs in high-grade PIN was almost identical with
the strength of expression in the corresponding invasive carcino-
mas (HDAC1: r¼0.961, Po0.001, HDAC2: r¼0.756, Po0.001,
HDAC3: r¼0.694, Po0.001), indicating that HDAC overexpres-
sion is an early event in prostate carcinogenesis.
Correlation of HDAC isoform expression with
clinicopathological factors and survival
HDAC1 (P¼0.006) and HDAC2 (P¼0.047) expression but not
HDAC3 (P¼0.584) expression correlated positively with Gleason
scores (Table 1), with high-grade tumours expressing both
isoforms at higher rates. In addition, expression of HDAC1
(P¼0.032), HDAC2 (P¼0.002) and HDAC3 (Po0.001) correlated
significantly with the Ki-67-positive proliferative fraction of
prostate cancer cells (Table 1). This indicates that the interlink
between HDAC activity and cell differentiation, as well as cell
proliferation, which has been proposed on the basis of cell culture
models of human tumours, can be measured and thus confirmed
in human prostate cancer.
To determine the probability of 7-year DFS, the postoperative
Kattan nomogram was applied. Probability of postoperative DFS
was lower in the HDAC1 high vs HDAC1 low group (median
Kattan score: 183 vs 163, median DFS probability: 0.6 vs 0.8) and in
the HDAC2 high vs HDAC2 low group (median Kattan score: 183
vs 154, median DFS probability: 0.6 vs 0.83) but not in the HDAC3
high vs HDAC3 low group (median Kattan score: 175 vs 181,
median DFS probability: 0.7 vs 0.6) (Table 1). However, only the
differences for HDAC2 were statistically significant (score:
HDAC1: P¼0.260, HDAC2: P¼0.034, HDAC3: P¼0.979; DFS
probability: HDAC1: P¼0.203, HDAC2: P¼0.036, HDAC3:
P¼0.946) (Table 1).
Univariate survival analysis in our cohort demonstrated that
patients with high HDAC1, 2 and 3 expression were prone to
earlier disease relapse (Table 2, Figure 2). However, statistical
significance was reached only for HDAC2. By stratifying patients
for Gleason groups, we found that differences in relapse-free
survival in dependence of HDAC2 expression were especially
prominent in the subgroup of patients with Gleason 7 tumours
(Gleason 2–6: P¼0.833, Gleason 7: P¼0.008, Gleason 8–10:
P¼0.272).
The effect of HDAC2 on patient prognosis became even more
pronounced in the multivariate survival analysis (Table 3) under
inclusion of stage, grade and status of resection margins and
preoperative PSA, which demonstrated an independent prognostic
significance of HDAC2 expression (P¼0.02, Hazard ratio¼2.4).
In a multivariate survival analysis under additional inclusion of the
proliferative fraction in the subgroup of patients for whom data on
Ki-67 index were available, HDAC2 expression retained its
prognostic significance (P¼0.03, Supplementary Table S1).
DISCUSSION
This is the first comprehensive immunohistochemical analysis
of the expression of several class I HDAC proteins (1, 2 and 3) in
prostate cancer. In our study, we found all the three isoforms
highly expressed in the majority of cancer cases and in the
corresponding PIN lesions, indicating that upregulation of class I
HDACs is an early event in prostate carcinogenesis. We assume
that increased expression of these proteins is accompanied by
increased overall activity. This view is supported by the fact that
clear-cut correlations between expression patterns and several
clinicopathological factors, as well as patient survival, were evident
for selected isoforms. However, whether mutations might impair
the activity of overexpressed HDACs in prostate cancer must be
clarified in further studies.
High expression levels of class I HDACs correlated with tumour
dedifferentiation and higher proliferative fractions (measures by
Ki-67) in prostate carcinoma, which is in line with in vitro studies,
Table 2 Patient survival in dependence of several clinicopathological
factors and HDAC isoform expression (n¼150)
Characteristic
No. of
cases
No. of
events
Mean
PSA-relapse-free
time (±s.e.)
in months P-value
HDAC1 expression 0.256
Low 53 18 112 (±10)
High 97 41 97 (±9)
HDAC2 expression 0.004
Low 42 9 134 (±13)
High 108 50 86 (±7)
HDAC3 expression 0.089
Low 9 1 148 (±15)
High 141 58 101 (±7)
Pre-OP PSA 0.006
p10ngml
 1 72 20 117 (±8)
410ngml
 1 73 37 75 (±10)
Age 0.336
p65 105 44 99 (±9)
465 45 15 108 (±12)
pT stage 0.003
pT2 78 22 111 (±9)
pT3/pT4 72 37 84 (±10)
Histological grade (Gleason) o0.001
Gleason sum 2–6 59 12 127 (±9)
Gleason sum 7 51 22 95 (±12)
Gleason sum 8–10 40 25 50 (±8)
R-status 0.006
R0 79 23 122 (±9)
R1 71 36 76 (±10)
Ki-67 index 0.010
p10% 95 34 104 (±8)
410% 34 21 62 (±14)
HDAC¼histone deacetylase. P-values were calculated with the log-rank test.
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swhich showed that high HDAC activity leads to tumour
dedifferentiation and enhanced tumour cell proliferation (Munster
et al, 2001; Floryk and Huberman, 2005; Uchida et al, 2005).
Expression of HDAC isoforms have been analysed by Waltregny
et al (2004) in prostate cancer cells and a small set of prostate
cancer tissue on mRNA and protein level. In their study, the
authors did not find differences of HDAC1 expression between
normal and malignant prostate tissue. In contrast, Halkidou et al
(2004) reported an overexpression of HDAC1 protein in neoplastic
prostate tissue, which was especially pronounced in hormone
refractory prostate cancers. This is basically in line with our
finding of higher HDAC levels in more aggressive tumours, even
though the tumours of our cohort represent untreated primaries,
most of which are supposedly hormone-naı ¨ve. Apart from a study
on HDAC1 and HDAC3 expression in breast cancer describing an
overexpression of both isoforms (Krusche et al, 2005), reports on
expression patterns of distinct HDAC isoforms in tumour entities
are sparse and most of the cohorts investigated were of a small
sample size.
Our survival analyses clearly demonstrate that high HDAC2
expression is associated with shortened patient relapse-free
survival time in prostate cancer, which is especially prominent in
the clinically important and prognostically heterogeneous sub-
group of patients with Gleason 7 carcinomas. This not only hints at
an important role of this isoform in prostate cancer progression
but also suggests HDAC2 expression as a novel prognostic marker
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Figure 2 Kaplan–Meier survival curves in dependence of Gleason grade and class I HDAC expression patterns. PSA-relapse-free survival in dependence
of (A) Gleason grade, (B) HDAC1, (C) HDAC2 and (D) HDAC3 expression. P-values were calculated with the log-rank test.
Table 3 Cox regression analysis with inclusion of HDAC2 expression
(n¼145)
Overall survival
HR 95%CI P-value
HDAC2 expression
Low 1.000
High 2.363 1.150–4.856 0.019
Pre-OP PSA
p10ngml
 1 1.000
410ngml
 1 1.542 0.884–2.691 0.127
Tumour stage
pT2 1.000
pT3/pT4 1.557 0.830–2.919 0.168
Gleason sum
2–6 1.000
7 2.795 1.325–5.898 0.007
8–10 3.131 1.403–6.989 0.005
R-status
R0 1.000
R1 1.440 0.789–2.631 0.235
CI¼confidence interval; HDAC¼histone deacetylase; HR¼hazard ratio.
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sfor prostate cancer. Our findings are supported by a significant
lower probability of DFS for patients with HDAC2 high tumours
when compared with patients with HDAC2 low tumours as
calculated by the respective Kattan nomogram. However, the
finding that HDAC2 is an independent prognosticator in prostate
cancer ought to be verified in a larger prospective study.
Technically, we found the evaluation of HDAC2 immunostainings
rather straightforward, as the percental nuclear immunoreactivity
was relatively independent of varying antibody concentrations.
This is a prerequisite for a robust semiquantitative evaluation and
is likely to reduce interlab variability and makes HDAC2 an
interesting candidate prognostic marker for further validation.
It is possible that the prognostic value of HDAC2 expression is
based on its strong correlation with the proliferative fraction.
However, uncontrolled cell proliferation is only a single but not the
decisive feature of malignancy. Other effects of aberrant HDAC
expression in prostate cancer relevant to tumorigenesis, such as
altered cell migration (Rombouts et al, 2002; Klisovic et al, 2005),
invasive potential or increased angiogenesis (Kim et al, 2001, 2004;
Kwon et al, 2002; Qian et al, 2006) might contribute to the dismal
prognosis of patients with HDAC2 high tumours, but this is so far
not proven experimentally for this tumour entity. Also, in a
multivariate Cox analysis with inclusion of the Ki-67 fraction,
HDAC remained an independent prognostic factor, whereas Ki-67
failed significance.
The fact that HDAC1 expression correlated strongly with
tumour dedifferentiation indicates a prominent role of this
isoform in the control of prostate tumour differentiation. The
observation that HDAC1 nonetheless had no significant impact on
patient prognosis might be explained by the fact that malignant
tumour behaviour is a composition of the above-mentioned
plethora of factors and is not determined by differentiation alone.
The high percentage of HDAC3 positivity (95%) in prostate
cancer naturally compromised valid correlations and survival
analyses but may make this isoform interesting in terms of a
therapy target.
Functionally, a growth inhibition of prostate cancer cells by
administration of HDIs has already been shown both in vitro and
in animal models (Butler et al, 2000; Kuefer et al, 2004; Thelen
et al, 2004; Fronsdal and Saatcioglu, 2005; Gediya et al, 2005;
Myzak et al, 2006). Divergent effects of therapeutic concentrations
of the HDAC inhibitors SAHA and VPA on tumour cell cycle, with
the former inducing a G2/M arrest and the latter inducing a G1
arrest, were reported for other tumour cell lines as well (Takai
et al, 2004a,b). An important role of class I HDACs, especially
HDAC3, on cell proliferation has also been reported for other
tumour entities (Wilson et al, 2006), which again makes it an
interesting therapy target.
Very recently, a variety of fusion genes have been discovered in
prostate cancer, which appeared to be centrally involved in
carcinogenesis. In this context, it should be noted that HDAC1 was
associated with an upregulation of the androgen-responsive
gene ERG, which results from a gene fusion of TMPRSS2 with
oncogenic ETS factors (Iljin et al, 2006). So far, it is unknown if
other class I HDAC isoforms are upregulated by genomic
alterations as well.
In summary, this study demonstrated that the three class I
HDAC isoforms 1, 2 and 3 are highly expressed in a considerable
fraction of adenocarcinomas of the prostate. High expression levels
of HDAC2 have a highly significant negative prognostic impact in
terms of PSA relapse-free survival times. The consistently high rate
of HDAC3 positivity in prostate cancer might be of interest for
further exploratory therapeutic studies. We hypothesize that the
outcome of patients who are going to be treated with HDIs being
currently in clinical trials is likely to be influenced by the
expression patterns of HDAC isoforms, which should be the focus
of further analyses.
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